Recent studies have linked AstraZeneca’s type-2 diabetes drug Kombiglyze with higher rates of heart failure and death. Studies also suggest it may increase the risk of pancreatitis, pancreatic cancer, and rhabdomyolysis.
What You Can Do & How We Can Help
The Schmidt Firm, PLLC is currently accepting Kombiglyze induced injury cases in all 50 states. If you or somebody you know was diagnosed with pancreatic cancer, you should contact our lawyers immediately for a free case consultation. Please use the form below to contact our Defective Drug Litigation Group or call us toll-free 24 hours a day at (866) 920-0753.
FDA Evaluating Rhabdomyolysis Risk
The FDA is evaluating a potential signals of a serious risk and new safety information linking DPP4 diabetes drugs and rhabdomyolysis. This potentially life-threatening kidney side effect was identified by the FDA Adverse Event Reporting System (FAERS) between April and June 2017.
What is Kombiglyze?
Kombiglyze contains a combination of saxagliptin (Onglyza) and metformin. It belongs to a class of drugs known as “incretin mimetics,” which mimic digestive hormones called incretins. This causes the pancreas to make more insulin, which helps lower blood-sugar.
Kombiglyze and Pancreatic Cancer
In March 2013, the FDA announced that it was investigating reports linking pancreatitis and pre-cancerous pancreatic tumors with diabetes drugs in the incretin mimetic class. Some experts are now concerned about a possible risk of pancreatic cancer, one of the rarest but deadliest of all cancers.
The FDA concern was based on a study published by Diabetes in which researchers warned:
“Since the standard of care of a pancreatic neuroendocrine tumor, because of the risk of conversion to malignancy, even if benign, is surgical resection [i.e. removal], patients exposed to incretin therapy would seem to be at increased risk of requiring pancreatic surgery.”
Kombiglyze and Heart Failure
In February 2014, the FDA announced that it would review the heart risks associated with Kombiglyze. They were concerned about results of a clinical trial linking saxagliptin with a 27% increased risk of hospitalization for heart failure. After reviewing the study for a year, the FDA also warned that Kombiglyze might increase a patient’s risk of death.
What is the problem?
The Schmidt Firm, PLLC is nationally recognized as a class action law firm, but our lawyers are not filing a Kombiglyze class action against AstraZeneca. Instead, we are filing individual lawsuits on behalf of people who were severely injured by side effects.
About Class Actions
The problem with class action lawsuits is that members with serious injuries may not feel like their case got the individual attention it deserved. In some class actions, members have to accept “low-ball” settlements, higher attorneys’ fees, and never get to see their case taken to trial.
Why Our Law Firm is Filing Individual Lawsuits as Opposed to a Class Action
Our attorneys specialize in helping victims of defective drugs file lawsuits against pharmaceutical companies. We believe there is no excuse for failing to warn doctors or patients about life-threatening side effects of medications. If you decide to file a lawsuit, we may be able to help you seek compensation and justice for your injury, medical expenses, lost income, disability, and more.
Do I have a Kombiglyze Lawsuit?
The Schmidt Firm, PLLC is currently accepting Kombiglyze induced injury cases in all 50 states. If you or somebody you know was diagnosed with pancreatic cancer, you should contact our lawyers immediately for a free case consultation. Please use the form below to contact our Defective Drug Litigation Group or call us toll-free 24 hours a day at (866) 920-0753.
Attention Lawyers: We consider a referral from another law firm to be one of the greatest compliments. If your firm is interested in referring us a case or for us to send you a list of previous award judgments and/or average referral fees, please visit the Lawyer Referral section of our website.
The Schmidt Firm, PLLC has been recognized as one of the nation’s leading plaintiffs' law firms and handles cases in all 50 states. We are very proud of our legal achievements, but equally self-respecting of our firm's reputation for providing personal attention to each and every client we represent.
